SML3913
VU0486846
≥98% (HPLC)
别名:
VU-0486846, (2R)-3,4-Dihydro-N-[(1S,2S)-2-hydroxycyclohexyl]-4-[[4-(1H-pyrazol-1-yl)phenyl]methyl]-2H-1,4-benzoxazine-2-carboxamide, (2R)-N-[(1S,2S)-2-Hydroxycyclohexyl]-4-[(4-pyrazol-1-ylphenyl)-methyl]-2,3-dihydro-1,4-benzoxazine-2-carboxamide, VU 0486846
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Biochem/physiol Actions
Orally active, CNS-penetrant, muscarinic acetylcholine receptor M1-selective positive allosteric modulator (PAM) without agonist activity or adverse cholinergic toxicity.
VU0486846 is an orally active, CNS-penetrant and highly selective muscarinic acetylcholine receptor M1 positive allosteric modulator (PAM) with little agonist activity (rat M1 EC50 = 230 nM, 93% ACh max; agonist EC50 > 10 μM) or adverse cholinergic toxicity. VU0486846 improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice (10 mg/day via drinking water), as well as enhances recognition memory and reverses 3 mg/kg risperidone-induced deficits in acquisition of contextual fear conditioning in rats in vivo (3-10 mg/kg i.p.).
VU0486846 is an orally active, CNS-penetrant and highly selective muscarinic acetylcholine receptor M1 positive allosteric modulator (PAM) with little agonist activity (rat M1 EC50 = 230 nM, 93% ACh max; agonist EC50 > 10 μM) or adverse cholinergic toxicity. VU0486846 improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice (10 mg/day via drinking water), as well as enhances recognition memory and reverses 3 mg/kg risperidone-induced deficits in acquisition of contextual fear conditioning in rats in vivo (3-10 mg/kg i.p.).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable